DoW Duchenne Muscular Dystrophy, Clinical/Translational Research Award

The Duchenne Muscular Dystrophy Clinical/Translational Research Award is administered by the Defense Health Agency through the Congressionally Directed Medical Research Programs as part of the Duchenne Muscular Dystrophy Research Program. This program was initiated by Congress to support high-impact biomedical research focused on Duchenne muscular dystrophy, a severe genetic disorder affecting muscle function. The overarching vision of the program is to preserve and improve function and quality of life across the lifespan of individuals affected by the disease, while also advancing therapeutic development that benefits both military families and the broader public. The purpose of this funding opportunity is to support advanced translational research projects that move promising scientific discoveries toward clinical application. The award emphasizes research that bridges laboratory findings and clinical practice through a reciprocal exchange of knowledge between basic and applied research. Projects must go beyond early-stage or proof-of-concept work and demonstrate potential for near-term clinical impact. The program strongly encourages studies that address therapies applicable across the full lifespan, including pediatric and nonambulatory populations, and allows for pilot clinical trials and clinical trial readiness efforts. Funding is offered under two distinct levels designed to accommodate varying project scopes. Funding Level 1 supports smaller and less complex studies with a maximum period of performance of three years, while Funding Level 2 supports larger, more complex studies with up to four years of support. Budget caps vary depending on whether a single principal investigator or a partnering investigator model is used, with maximum awards reaching up to 1.90 million dollars. Funds may be used for research-related costs including personnel, data collection, and limited travel for collaboration and dissemination, but must adhere to specific restrictions outlined in the program guidance. Eligibility is broad and inclusive, allowing applications from domestic and international organizations, including for-profit and nonprofit entities, academic institutions, and government organizations. Principal investigators must be independent researchers affiliated with an eligible organization. The program also offers a Partnering Principal Investigator Option designed to foster collaboration, including opportunities for early-career investigators and interdisciplinary researchers transitioning into the Duchenne muscular dystrophy field. Cost sharing is not required, which lowers barriers to entry for a wide range of applicants. The application process follows a two-step submission model. Applicants must first submit a pre-application in the form of a Letter of Intent through the Electronic Biomedical Research Application Portal. This is followed by a full application submitted through either Grants.gov or eBRAP depending on the applicant type. The full application requires extensive documentation including a project narrative, technical and lay abstracts, statement of work, impact statement, transition plan, and supporting documentation. Clinical trials require additional documentation such as a Clinical Strategy Statement. Applications are evaluated through a two-tier review process consisting of peer review and programmatic review. Peer review assesses scientific merit, feasibility, statistical rigor, and impact, while programmatic review considers alignment with program priorities and overall portfolio balance. Key evaluation criteria include research design quality, clinical relevance, potential for impact, and feasibility of transitioning findings into clinical practice. Applications must also demonstrate access to necessary resources and a clear plan for data sharing. The timeline for this opportunity includes a pre-application deadline in early September followed by a full application deadline later in the same month. Peer review is expected to occur in December, with programmatic review in February of the following year. Awards are anticipated to be made by September of the following fiscal year, with funding availability extending several years beyond the award date. This opportunity appears to be part of an annual funding cycle, reflecting ongoing federal investment in advancing treatments for Duchenne muscular dystrophy.

Strong preliminary data and clear clinical translation pathways are critical; proposals must demonstrate feasibility, rigorous design, and near term impact on patient outcomes